0000950170-24-074839.txt : 20240618
0000950170-24-074839.hdr.sgml : 20240618
20240618160503
ACCESSION NUMBER: 0000950170-24-074839
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240611
FILED AS OF DATE: 20240618
DATE AS OF CHANGE: 20240618
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Corvese Brian
CENTRAL INDEX KEY: 0001393207
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-29089
FILM NUMBER: 241051682
MAIL ADDRESS:
STREET 1: C/O ANTIGENICS INC.
STREET 2: 162 FIFTH AVENUE, SUITE 900
CITY: NEW YORK
STATE: NY
ZIP: 10010
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AGENUS INC
CENTRAL INDEX KEY: 0001098972
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 061562417
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3 FORBES ROAD
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 781-674-4410
MAIL ADDRESS:
STREET 1: 3 FORBES ROAD
CITY: LEXINGTON
STATE: MA
ZIP: 02421
FORMER COMPANY:
FORMER CONFORMED NAME: ANTIGENICS INC /DE/
DATE OF NAME CHANGE: 19991115
4
1
ownership.xml
4
X0508
4
2024-06-11
0001098972
AGENUS INC
AGEN
0001393207
Corvese Brian
C/O AGENUS INC.
3 FORBES ROAD
LEXINGTON
MA
02421
true
false
false
false
false
Stock Option
13.25
2024-06-11
4
A
false
750
0.00
A
2034-01-26
Common Stock
750
750
D
Options were granted on January 26, 2024 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 11, 2024. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests over three years with one-third of the award vesting on January 26, 2025 and the balance vesting in equal quarterly installments thereafter. The Stock Options were granted prior to the 1 for 20 reverse stock split, representing 15,000 Stock Options with an exercise price of $0.66.
/s/Christine Klaskin, as Attorney-in-Fact for Brian Corvese
2024-06-18